Discovery of [18F]N-(2-(Diethylamino)ethyl)-6-fluoronicotinamide: A Melanoma Positron Emission Tomography Imaging Radiotracer with High Tumor to Body Contrast Ratio and Rapid Renal Clearance
摘要:
The high melanoma uptake and rapid body clearance displayed by our series of [I-123]liodonicotinamides prompted the development of [F-18]N-(2-(diethylamino)ethyl)-6-fluoronicotinamide ([F-18]2), a novel radiotracer for PET melanoma imaging. Significantly, unlike fluorobenzoates, [F-18]fluorine incorporation on the nicotinamide ring is one step, facile, and high yielding. [F-18]2 displayed high tumor uptake, rapid body clearance via predominantly renal excretion, and is currently being evaluated in preclinical studies for progression into clinical trials to assess the responsiveness of therapeutic agents.
[EN] NICOTINAMIDE DERIVATIVES<br/>[FR] DÉRIVÉS DE NICOTINAMIDE
申请人:AUSTRALIAN NUCLEAR SCIENCE TEC
公开号:WO2009129573A1
公开(公告)日:2009-10-29
A compound comprising a pyridine carboxamide structure, for use in imaging or treating melanoma, is described. An aromatic ring in the structure is substituted with a radiohalogen atom and the substitution on the amide nitrogen atom is such that the compound binds to melanin.
A compound comprising a pyridine carboxamide structure, for use in imaging or treating melanoma, is described. An aromatic ring in the structure is substituted with a radiohalogen atom and the substitution on the amide nitrogen atom is such that the compound binds to melanin.
Discovery of [<sup>18</sup>F]<i>N</i>-(2-(Diethylamino)ethyl)-6-fluoronicotinamide: A Melanoma Positron Emission Tomography Imaging Radiotracer with High Tumor to Body Contrast Ratio and Rapid Renal Clearance
作者:Ivan Greguric、Stephen R. Taylor、Delphine Denoyer、Patrice Ballantyne、Paula Berghofer、Peter Roselt、Tien Q. Pham、Filomena Mattner、Thomas Bourdier、Oliver C. Neels、Donna S. Dorow、Christian Loc’h、Rodney J. Hicks、Andrew Katsifis
DOI:10.1021/jm9008423
日期:2009.9.10
The high melanoma uptake and rapid body clearance displayed by our series of [I-123]liodonicotinamides prompted the development of [F-18]N-(2-(diethylamino)ethyl)-6-fluoronicotinamide ([F-18]2), a novel radiotracer for PET melanoma imaging. Significantly, unlike fluorobenzoates, [F-18]fluorine incorporation on the nicotinamide ring is one step, facile, and high yielding. [F-18]2 displayed high tumor uptake, rapid body clearance via predominantly renal excretion, and is currently being evaluated in preclinical studies for progression into clinical trials to assess the responsiveness of therapeutic agents.